Please login to the form below

Not currently logged in

Approvals of generic Eloxatin suspended

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin, delaying competition to its fifth-biggest medicine

A US appeals court has temporarily suspended approvals of generic versions of sanofi-aventis' Eloxatin (oxaliplatin), delaying competition to its fifth-biggest medicine.

France's largest drugmaker has contested the US Food and Drug Administration's (FDA) decision to approve copies of the treatment. The ruling forces rivals, including Hospira and Teva who recently obtained FDA approval, to halt shipments of the drug.

Teva spokesperson Denise Bradley confirmed that the company is "not shipping further product until the legal issue is resolved… We are hopeful to have a decision in the near future."

Hospira stated in a US Securities and Exchange Commission filing that the suspension remains in effect "until such time as the court has an opportunity to consider arguments on this matter."

Eloxatin generated €1.35bn ($1.9bn) in sales for sanofi-aventis last year. The company is under pressure as several of its best-selling drugs, including the blood-thinner Plavix, face generic competition.

18th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...